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Treatment results for neuroblastoma in Denmark have been poorer than in other Nordic countries, so we investigated whether a
change in incidence, stage distribution and survival had occurred between 1981 and 2000. Clinical data were retrieved from the
medical charts of 160 children o15 years of age with extra-cranial neuroblastoma (n¼139) or ganglioneuroblastoma (n¼21)
diagnosed in Denmark between 1981 and 2000. The minimal follow-up time was 52 months. Statistical analyses were performed in
STATA. The incidence was 8.55 per million children below 15 years of age (world standard 9.6) and 42.6 per million children below
12 months of age, and it has remained unchanged since 1970. The median age at diagnosis was 27 months. In all, 32% of the children
were aged below 12 months at diagnosis, 53% had metastatic disease and in 12% the diagnosis was made incidentally. Prognostic
factors such as age, stage and site of primary tumour were the same as in other studies and did not change. During the study period,
the mortality rate decreased steadily, and the 5-year survival rate increased from 38% in 1981–1985 to 59% in 1996–2000,
corresponding to the level found in other Western countries. Increased survival was also seen in children with metastatic disease.
Participation in international studies, better supportive care and possibly postoperative autologous stem cell transplantation may have
contributed to the increased survival.
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Neuroblastoma is the most frequent solid tumour outside the
central nervous system in children below 15 years of age in
Denmark with an annual incidence of 8–10 new cases. The most
recent population-based study of neuroblastoma in Denmark in
1986 included 253 children diagnosed during 1943–1980 (Carlsen
et al, 1986; Carlsen, 1994). These studies showed increases in
incidence especially in children below 12 months of age, in the
incidence of incidentally diagnosed neuroblastomas (Carlsen,
1990) and in the survival rate mainly because of a more favourable
age and stage distribution; it was noted, however, that survival was
significantly better in children who were treated with chemo-
therapy (Carlsen et al, 1986; Carlsen, 1994).
Since 1985, all Danish children with solid tumours have been
registered in the Nordic Solid Tumour Registry. The annual report
from the registry in 2000 showed that the survival of neuro-
blastoma in Denmark during 1985–1994 was significantly poorer
than in the other Nordic countries, especially Finland.
We aimed to investigate whether neuroblastoma during the
period 1981–2000 showed changes in incidence and mortality rate
since the earlier population-based study in Denmark. We also
wished to determine whether survival, especially in children
with metastatic neuroblastoma, had improved and whether the
distribution of known important prognostic factors (i.e. age,
stage and localisation of primary tumour) had changed, both
during the study period and in comparison with the earlier study
(Carlsen et al, 1986).
MATERIALS AND METHODS
Patients were identified from four different sources: (1) The
National Cancer Registry of Denmark, (2) The Nordic Solid
Tumour Registry, (3) the databases of the four Danish centres of
paediatric oncology and (4) the histopathology databases at the
Danish Departments of Pathology. A total of 160 neuroblastoma
(n¼139) or ganglioneuroblastoma (n¼21) cases were identified
in children below 15 years of age, (86 boys, 74 girls) either
histologically verified (n¼145) or with increased urinary vanillic
mandelic acid (VMA) or homovanillic acid (HVA), together with
the detection of malignant cells in the bone marrow (n¼15).
Minimal follow-up was 51.6 months after diagnosis, and at latest
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alive with no evidence of disease and three had emigrated in
first complete remission, 4, 4 and 5 years, respectively, after
diagnosis. The populations used were yearly averages at ages o1,
1–4 and 5–14 years during the study period as reported by
Statistics Denmark (www.dst.dk). Clinical data were registered
after a critical review of all medical charts. Cases of incidentally
diagnosed neuroblastoma were defined as those diagnosed during
a routine paediatric examination or by an examination for an
unrelated disorder, such as chest X-ray, because of suspected lower
pulmonary infection.
Disease stage was classified according to the International
Neuroblastoma Staging System (INSS) (Brodeur et al, 1993, 1994):
Stage 1: Tumour localised, completely removed surgically
with or without microscopic residual tumour.
Stage 2: Unilateral tumour incompletely removed, possibly
with tumour in ipsilateral lymph nodes.
Stage 3: Tumour infiltrating over the midline with or without
tumour tissue in regional lymph nodes; or unilateral
tumour with tumour tissue in contralateral lymph
nodes; or midline tumour with tumour tissue in
bilateral lymph nodes.
Stage 4: Primary tumour of any stage with metastases to bone,
bone marrow, remote lymph nodes, liver or other
organs in children over 12 months at diagnosis.
Stage 4S: Children o12 months of age with primary tumour
stage 1 or 2 and metastases to liver, skin or bone
marrow infiltration (with o10% malignant cells in
the bone marrow).
Treatment varied over time and by stage, that for stage 1 being
primary operation. All children with stage 2 had primary
operation, followed by chemotherapy in 66% and irradiation in
17% of cases. Almost all children with stages 3 and 4 were treated
with chemotherapy of which 75% were treated according to
international contemporary neuroblastoma protocols (OPEC/OJEC
(Shafford et al, 1984), (Vincristine, Cisplatinum, Etoposide,
Cyclophosphamide and Carboplatin; Pearson et al, 2008)).
Irradiation of the primary tumour was given to 20% of children
in stages 3 and 4.
From 1991, myeloablative chemotherapy followed by autologous
stem cell reinfusion was introduced for children over 12 months of
age with stage 4 disease after clearing the bone marrow of neuro-
blastoma cells; it consisted primarily of high-dose melphalan
þ/ busulfan, followed by reinfusion of autologous bone marrow
cells (before 1 January 1998) or peripheral stem cells (after 1
January 1998) without purging. Operations were performed at the
four university hospitals in Denmark responsible for the treatment
of children with cancer. Children with stages 1 and 2 were operated
at the time of diagnosis. Of the 27 children with stage 3, 20 were
operated before the start of chemotherapy. Before 1990, most
children with stage 4 disease were operated primarily; since 1990,
however, all children over 12 months of age were operated only
after 4–6 months of preoperative chemotherapy (Pearson et al,
2008). The extent of macroscopic radicality was stated by the
operating surgeon.
The results of 23 patients with stage 4 over 12 months of age
diagnosed between 1990 and 1999 were included in a multicentre
international European randomised study (Pearson et al, 2008).
Therapy for stage 4S varied considerably.
Statistical methods
Incidences were calculated from the background populations and
age was standardised according to the world standard population,
and comparisons were performed by the w
2 test. Survival curves
were performed by the Kaplan–Meier method and compared by the
log-rank test. P-values below 0.05 were considered statistically
significant. All analyses were performed in STATA 9.
RESULTS
There were 86 boys and 74 girls, ratio: 1:1.16. The median age at
diagnosis was 27 months (mean 33 months; range: 0–154 months).
For children aged 12 months with metastatic disease, the median
age at diagnosis was 40 months (mean 50 months; range: 12–154
months). For patients alive at the time of follow-up or at
emigration (n¼69), the mean time of follow-up was 174 months
(range: 52–311 months). For those who died, the mean survival
was 20 months (range: 0–189 months).
Incidental neuroblastoma was diagnosed in 12% of neuro-
blastoma cases (19 out of 160) (Table 1), and there was no
difference in the incidence of such cases between the two 10-year
periods. Fourteen cases were diagnosed in children o12 months
of age, one in a 21-month-old child and four between ages 31–43
months. A tumour was discovered in the mediastinum in seven
children during an X-ray examination for unrelated symptoms,
and by abdominal examination in 12 children (by palpation or
ultrasonography). Three of those with incidentally discovered
neuroblastoma died, one with stage 3 at 3 months, 5 weeks
after diagnosis, one infant with stage 4S died from a genetically
inherited lung disease within 2 months of diagnosis and one
tetraplegic boy with stage 3 neuroblastoma died from pneu-
monia unrelated to neuroblastoma 15 years after diagnosis. All
seven children with incidental neuroblastoma localised in the
mediastinum survived.
The incidence of all neuroblastomas during 1981–2000, by age
and period, are shown in Table 2, with that in children below 15
years being 8.55 per million and 9.6 per million being age
standardised. There was no difference in incidence between the
two 10-year periods (w
2: P¼0.95), either in children below or over
12 months at diagnosis (w
2: P¼0.21 and P¼0.30, respectively).
The 52 children (including 14 incidental cases) aged below 12
months at diagnosis represented an incidence of 42.6 per million;
40% of these infants were below 3 months at diagnosis. There was
no difference in the age and stage distribution between the two 10-
year periods (Table 2).
Figure 1 shows the survival curves for the four 5-year periods.
There are significant differences between the two 10-year periods
(log rank: Po0.05). Also, for children over 12 months of age with
metastatic disease, the survival curves for the two 10-year periods
differ significantly (Figure 2, log rank: Po0.05). For children
diagnosed during 1981–1990, the overall survival (OS) was 37%,
whereas it was 54% for those diagnosed during 1991–2000
(P¼0.01) (Table 3). The OS increased from 32% (1981–1985) to
Table 1 The age and stage distribution, and the localisation of the
primary tumour in incidental cases
Total
N
Age 0–11
months
Age 12–23
months
Age 24+
months
Stage
16 3 1 2
24 2 2
37 7
4S 2 2
Total 19 14 1 4
Localisation of primary
tumour
Mediastinum 7 5 2
Retroperitoneum/
adrenal glands
10 8 1 1
Pelvis 2 1 1
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of the primary tumour, age at diagnosis and the stage all were
significant prognostic factors (Table 3). After adjustment for stage
and localisation, age had independent prognostic significance
(Po0.001).
The survival increased significantly for children with localised
tumours (stages 1–3 from 57% during 1981–1990 to 86% during
1991–2000 (P¼0.01 Fisher’s exact test).
During the first 12 months after diagnosis, the mortality rate
ratio (MRR) was significantly lower during the second 10-year
period when compared with the first (Po0.001) (Table 4). MRR
was especially high for children with stages 3 and 4S during the
first 6 months after diagnosis and was significantly higher than for
stages 1, 2 and 4 (Po0.001.) A considerable contribution to the
improved prognosis during the latter 10-year period was caused by
a reduced mortality, especially during the first 3 months after
diagnosis, as only 4% (3 out of 79) of children diagnosed during
1991–2000 died, compared with 17% (14 out of 81) of those
diagnosed during 1981–1990 (Po0.01 Fisher’s exact test) (data
not shown).
Regarding the period later than 12 months after diagnosis, the
MRR was lower for children diagnosed during 1991–2000
compared with 1981–90, although not statistically significant
(Table 4). The MRR was significantly lowest for stages 1 and 2
more than 12 months after diagnosis, and highest for stage 4 more
than 12 months after diagnosis but not earlier. For children with
stages 3 and 4, no difference in OS could be shown whether the
surgical procedure was radical or non-radical (data not shown).
DISCUSSION
In this population-based study of neuroblastoma in Denmark over
a 20-year period, the age-standardised incidence was 9.6 per
million overall and 42.6 per million below 12 months of age at
diagnosis, similar to those found in Denmark during 1976–1980
(Carlsen, 1986, 1994) and in other population-based studies after
1975 in which no screening for neuroblastoma had taken place.
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Figure 1 Survival of neuroblastoma in Denmark during the four 5-year
periods.
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Figure 2 Survival of children 412 months of age with stage 4
neuroblastoma during two 10-year periods.
Table 2 Age-specific incidence and stage distribution of neuroblastoma
and ganglioneuroblastoma
1981–1990
N
1991–2000
N
Incidence
per million
during the
study period
Age at diagnosis
o12 months 28 24 42.6
12–23 months 9 13 16.1
24–59 months 28 30
459 months 16 12 2.2
Total 81 79
Age-specific incidence per million 8.51 8.60 8.55
Age-standardised incidence 9.6
Stage at diagnosis
Stage 1 4 8 7.5%
Stage 2 15 11 16.3%
Stage 3 18 9 16.9%
Stage 4 38 46 51.3%
Stage 4S 6 5 7.0%
Table 3 Number of patients, number of deaths, 5-year survival (%) with
95% CI
Number
of
children
Number
of
deaths
5-year
survival
(95 % CI)
Log-rank
test for
similar
pattern
of survival (P)
Period of diagnosis
1981–1990 81 53 37 (27–47) P¼0.01
1991–2000 79 38 54 (43–65)
Age (months)
o12 52 14 77 (63–86) Po0.001
12–23 22 11 50 (28–68)
24–59 58 41 31 (20–43)
X60 28 25 14 (5–30)
Stage
1, 2 38 3 92 (77–97) Po0.001
3 27 17 44 (26–62)
4 84 66 23 (14–32)
4S 11 5 64 (30–85)
Localisation
Neck/mediastinum/
pelvis
31 7 77 (58–88) Po0.001
Abdominal/adrenal 129 84 38 (30–46)
CI¼confidence interval. Log-rank test for similar patterns of survival.
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10 years of the study period when it improved for all stages, and
also for children over 12 months with metastatic disease (Bernstein
et al, 1992; Powell et al, 1998; Spix et al, 2001, 2006; Cotterill et al,
2001a). Thus, no change has occurred in the incidence of
neuroblastoma in Denmark during the past 30 years and, more
importantly, the age distribution has not changed either.
The absence of change in incidence is in contrast to other
European regions in which the overall age-standardised incidence
increased from 8.4 to 11.6 during almost the same 20-year study
period. This was primarily caused by an increase among 0 to
12-month-old children in all regions except the British Isles and
the Nordic region (Denmark, Norway, Finland and Iceland), where
the incidences were constant over the study period (Spix et al,
2006). The increase in neuroblastoma incidence in children below
12 months of age was closely correlated with an increase in overall
survival. The increased incidence in other European regions
cannot be explained by the extent of screening that has taken place
only in parts of Germany during part of the study period, although
an increased incidence was found in the screened population
compared with the control population (Schilling et al, 2002).
Screening was also performed in a French region and in smaller
areas of Great Britain (Powell et al, 1998).
The increased incidence observed in some regions is probably
because of an increased number of incidentally diagnosed
neuroblastomas, predominantly in the infant group, especially in
Germany, France and Austria. More frequent routine health checks
are provided in these countries as compared with the UK and
Denmark. More children are examined by paediatricians, and
greater availability of ultrasound may have contributed to an
increase of asymptomatic patients diagnosed incidentally. Inci-
dental neuroblastoma was reported in 27% of Austrian and 34% of
German cases during this period in contrast to 7.7% in the UK,
although this covered only 15% of patients from two regions. This
also explains why the number and incidence of neuroblastomas in
children o12 months of age diagnosed in Denmark during our
study period was lower than that in France, Germany and Austria
(Powell et al, 1998; Spix et al, 2006). Incidental neuroblastomas
during our study period represented 12% of cases (n¼19),
considerably lower than in Germany, France and Austria, and a
little higher than the figures from two regions in the UK. There was
no increased trend in incidental cases over the 20-year period and
the incidence was similar to that during 1971–80 when 14% (15) of
cases were detected incidentally (Carlsen, 1990).
The stage distribution in this study was unchanged during the
study period and was exactly the same as during 1943–1980 in
Denmark (Carlsen, 1986); 53% of patients had stage 4 disease.
Compared with France, Austria and Germany, the percentage of
stages 1 and 2 did not differ, about 24%, but was markedly higher
than in the UK. The proportion with stage 4 was higher in
Denmark, but when stage 3 was included the figures were different
from those in France, Germany and Austria, but lower than those
in the UK (Powell et al, 1998). In this material, 80% of tumours
were situated in the adrenal glands or the retroperitoneum, as in
the earlier study (Carlsen, 1986) and in a report from the European
Neuroblastoma Study Group (Cotterill et al, 2000). All significant
prognostic clinical parameters such as age, stage distribution and
localisation of primary tumour did not differ from other
international studies, in which no form of screening had taken
place, or from the earlier Danish study.
This is an important observation as age below 12 months is one
of the strongest prognostic factors (Carlsen, 1986; Cotterill et al,
2000; Spix et al, 2001). A large European study showed that
survival was highest in Germany and France, where the incidence
below 12 months was high, about 60 per million, whereas that in
England was 50% lower (Powell et al, 1998). In Finland, which
has the highest survival in the Nordic countries, a little more
than 50% of children with newly diagnosed neuroblastoma were
below 12 months compared with only 33% of Danish children
(Spix et al, 2001).
We showed a significant decrease in the MRR during the study
period, implicating that survival has increased significantly
because of improved therapy. Corresponding to this, a signifi-
cantly better survival was shown for children diagnosed during
1991–2000 compared with 1981–1990.
The observed increase in the 5-year survival of neuroblastoma
in Denmark during the four 5-year periods from 38% during
1981–85 to 59% during 1996–2000 is not explained by a change
in age or stage distribution, which was unchanged during the
period and also unchanged compared with the preceding 10-year
periods (Carlsen et al, 1986). Survival in Denmark, Norway
and Finland during 1993–97 was 61% (Spix et al, 2006), so the
observed survival rate of 59% in Danish children during 1996–
2000 is probably not significantly different from that of the two
other Nordic countries, and as the minimum follow-up is about 5
years, the figures are not expected to change significantly (Cotterill
et al, 2001b).
However, the survival rates in other Western countries, mainly
France and Germany, during 1993–1997 was 74%, probably
significantly higher than in Denmark during this period. One
explanation for this difference may be that the age-standardised
neuroblastoma rate was about 30% higher in the Western
countries than in Denmark during this period, almost exclusively
explained by a much higher incidence in children below 12 months
of age (Spix et al, 2006). This fact may render comparisons of
overall survival between the two groups difficult. It seems,
however, that the survival at 2–14 years was still higher in the
Western than in Nordic countries (53 vs 42%) (Spix et al, 2006).
A considerable part of the improved prognosis from the first to
the second 10-year period could be attributed to a significantly
decreased early mortality, especially during the first 6 months after
diagnosis during the second period. The survival of children with
stages 3 and 4S was considerably lower compared with other studies,
especially for early deaths. For stage 3, this was caused by
Table 4 MRR for each of the factors: diagnosis period, age, stage and
localisation of the primary tumour divided into the periods 0–12 months
and 412 months after diagnosis
Adjusted MRR (95% CI)
0–12 months after
diagnosis
412 months after
diagnosis
Diagnosis period
1981–1990 1 1
1991–2000 0.30 (0.13–0.66) 0.62 (0.36–1.06)
Age (months)
o12 1 1
12–23 1.42 (0.45–4.45) 2.69 (0.78–9.29)
24–59 0.83 (0.31–2.24) 5.60 (1.99–15.74)
X60 1.78 (0.65–4.86) 5.80 (1.96–17.17)
Stage
1, 2 0.47 (0.05–4.33)
a 0.03 (0.00–0.26)
0.15 (0.02–1.23)
b
3, 4S 6.15 (2.04–18.57)
a 0.53 (0.24–1.15)
0.21 (0.03–1.63)
b
41 1
Localisation
Neck/mediastinum/
pelvis
11
Abdominal/adrenal 1.09 (0.36–3.25) 1.77 (0.52–6.00)
CI¼confidence interval; MRR¼mortality rate ratio.
aDuring the period 0–6 months
after diagnosis.
bDuring the period 6–12 months after diagnosis.
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attempts at radical excision without neoadjuvant chemotherapy in
children with large abdominal tumours. During the second period,
most patients with stage 3 had preoperative chemotherapy allowing
the tumour to shrink and rendering secondary operation less risky.
Our analyses also showed a significantly increased survival of
children over 12 months with stage 4 neuroblastoma treated after
1990, in which autologous stem cell transplantation (ASCT) was
introduced compared with the earlier period. As initial response to
rapid COJEC was superior to OPEC/OJEC in a randomised study of
initial chemotherapy (Pearson et al, 2008), chemotherapy may, in
addition to myeloablative therapy, have had an impact on the
increased survival in this group treated after 1990. Also, Berthold
et al (2003) showed an increased survival in children over 12
months of age with stage 4 disease between 1990 and 2001, with a
survival of 44% during 1997–2001.
Multivariate analyses showed that the well-known prognostic
factors of age and stage, but not localisation of the primary
tumour, had independent prognostic significance, as had the time
of diagnosis. Myeloablative chemotherapy and ASCT had prog-
nostic significance in univariate analysis, but they had no
independent prognostic significance in multivariate analyses. The
effect of the completeness of the operation in children with stages 3
and 4 had prognostic significance neither in uni- nor multivariate
analyses.
In a population-based study of all cases of neuroblastoma in
Denmark during 1981–2000, no increase in incidence and no
change in the distribution of prognostic factors were shown
compared with a study up to 1980. The most prominent increase in
prognosis occurred during the second 10 years of the study period
when this improved for all stages, and also for children over 12
months with metastatic disease.
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